Abstract: The present invention relates to a conjugate of the formula P-L-I, wherein P is a peptide hormone effecting the metabolism of carbohydrates in vivo, L is a hydrolysable linker molecule consisting of Lp and Li, and I is a molecule capable of inhibiting the effect of the peptide hormone P on the metabolism of carbohydrates in vivo. Under in vivo conditions, the conjugate is the major compound. When the concentration of glucose increases in vivo, the concentration of the peptide hormone effecting the metabolism of carbohydrates in vivo also increases.

Abstract: The present invention relates to compositions and peptides having agonist activity towards both the human GLP-1 receptor and the human GLP-2 receptor, wherein the relative agonist activity of the dual peptide towards the human GLP-1 receptor (GLP-1Rrelative) is at least 0.01, and wherein the relative agonist activity of the dual peptide towards the human GLP-2 receptor (GLP-2rrelative) is at least 0.01, and wherein (GLP-1Rrelative)(GLP-2Rrelative) is at least 0.01, as well as methods of production and uses thereof. Further, the invention relates to lipidated analogs of the peptides. The invention further relates to the treatment or prophylactic treatment of human diseases, in particular gut and brain relates diseases or metabolic disorders, such as gastrointestinal inflammation, short bowel syndrome and Crohn's disease.